Skip to search.

Breaking News Visit Yahoo! News for the latest.

×Close this window

 Dow Down0.08% Nasdaq Down0.11%

TrovaGene, Inc. (TROV)

-NasdaqCM

6.95 Up 0.61(9.62%) May 23, 4:00PM EDT

Add to Portfolio
ProfileGet Profile for:
TrovaGene, Inc.
11055 Flintkote Avenue
Suite B
San Diego, CA 92121
United States - Map
Phone: 858-217-4838
Website: http://www.trovagene.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:14

Business Summary 

Trovagene Inc., a development stage molecular diagnostic company, focuses on the development and commercialization of proprietary diagnostic technologies for use in patient/disease screening and monitoring in various medical disciplines. The company’s urine-based testing platform facilitates to enhance the management of cancer care and women’s healthcare. Its proprietary urine-based molecular diagnostic tests are used to detect transrenal DNA and RNA that are cell-free nucleic acids found in urine. The company’s technology is applied in various testing, such as tumor detection and monitoring, prenatal genetic testing, infectious diseases, tissue transplantation, and forensic identification, as well as for patient selection in clinical trials. In addition, it owns rights to nucleophosmin-1, an informative biomarker for acute myeloid leukemia and mutations in the SF3B1 gene that are to be associated with chemotherapy response in chronic lymphocytic leukemia patients. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene Inc. in January 2010. Trovagene Inc. was founded in 1999 and is headquartered in San Diego, California.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on TrovaGene, Inc.

Key Executives 
 PayExercised
Dr. Antonius P. Schuh Ph.D., 49
Chief Exec. Officer and Director
412.00K0.00
Mr. Stephen L. Zaniboni MBA, CPA, 55
Chief Financial Officer and Principal Accounting Officer
279.00K0.00
Dr. Gary S. Jacob Ph.D., 66
Sec., Director, Member of Compensation Committee and Member of Audit Committee
N/AN/A
Dr. Charles P. Rodi Ph.D., 61
Chief Technology Officer and VP
N/AN/A
Dr. Mark Erlander Ph.D.,
Chief Scientific Officer
N/AN/A
Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders